In a window-of-opportunity study in patients with resectable SCCHN, treatment with xevinapant monotherapy resulted in a significant reduction in cIAP1 levels in tumor cells [67]. The gene discussed is BIRC2; the disease is head and neck squamous cell carcinoma.